Beam Therapeutics reports positive data from sickle cell therapy trial

CAMBRIDGE, Mass. - Beam Therapeutics Inc. (NASDAQ:BEAM), a $1.7 billion market cap biotechnology company currently trading near $17.44, reported updated data from 17 patients in its BEACON Phase 1/2 clinical trial of BEAM-101, showing consistent results in treating sickle cell disease (SCD) with severe vaso-occlusive crises. According to InvestingPro analysis, the company maintains a FAIR overall financial health score, despite the typical cash burn associated with clinical-stage biotech firms.

According to a press release statement, all patients treated with the base-editing therapy achieved hemoglobin F induction exceeding 60%, hemoglobin S reduction below 40%, and resolution of anemia. Patients required a median of one mobilization cycle and experienced rapid neutrophil and platelet engraftment. With the stock trading between its 52-week range of $13.53 to $35.25, InvestingPro data suggests the company is currently slightly undervalued based on its proprietary Fair Value model.

The safety profile remained consistent with busulfan conditioning, autologous hematopoietic stem cell transplantation, and underlying SCD. No vaso-occlusive crises were reported post-engraftment in any of the patients.

Patient follow-up ranged from 0.2 to 15.1 months as of the February 28, 2025 data cutoff. The company reported that increases in fetal hemoglobin, decreases in sickle hemoglobin, and resolution of anemia were durable for up to 15 months.

The trial also showed normalization or improvement in key markers of hemolysis, including indirect bilirubin, haptoglobin, lactate dehydrogenase, and reticulocytes following treatment.

Beam Therapeutics noted that one patient died four months after BEAM-101 infusion due to respiratory failure, which investigators determined was likely related to busulfan conditioning and unrelated to BEAM-101.

The company confirmed that enrollment is complete in both adult and adolescent cohorts of the BEACON trial, with 26 patients dosed as of June 13, 2025. Beam expects to dose a total of 30 patients by mid-2025 and share additional data by the end of the year. Analysts maintain an optimistic outlook, with price targets ranging from $20 to $80 per share. For deeper insights into BEAM’s financial health, growth prospects, and detailed analysis, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.

BEAM-101 is an investigational genetically modified cell therapy that uses base editing to increase production of non-sickling fetal hemoglobin in patients with sickle cell disease.

In other recent news, Beam Therapeutics Inc. has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for two of its investigational treatments: BEAM-101 for sickle cell disease (SCD) and BEAM-302 for alpha-1 antitrypsin deficiency (AATD). This status provides the company with benefits such as tax credits, FDA fee exemptions, and potential market exclusivity upon approval. BEAM-101, currently in a Phase 1/2 trial, has shown promising results in increasing fetal hemoglobin and decreasing sickle hemoglobin, crucial for alleviating SCD symptoms. Meanwhile, BEAM-302 has demonstrated efficacy in correcting the mutation responsible for AATD in early trials, with the FDA also granting it Regenerative Medicine Advanced Therapy (RMAT) designation. This designation may accelerate the development and review process, as the therapy addresses unmet medical needs in AATD patients.

Analyst firms have responded positively to Beam Therapeutics’ recent developments. BofA Securities upgraded the company’s stock rating to Buy, citing the promising data for BEAM-302 and setting a price target of $42.00. H.C. Wainwright also maintains a Buy rating with a target of $80.00, following the presentation of new data from the BEAM-302 trial. These advancements reflect growing confidence in Beam Therapeutics’ gene editing platform and its potential impact on treating genetic disorders.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.